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Enhanced Proliferation and Activation of Peripheral
Blood Mononuclear Cells in Patients with Psoriasis
Vulgaris Mediated by Streptococcal Antigen with
Bacterial DNA
Yi-Hua Cai1, Zhi-Yong Lu1, Ruo-Fei Shi1, Feng Xue1, Xiao-Ying Chen1, Meng Pan1, Wei-Ru Yuan1,
Han Xu1, Wei-Ping Li1 and Jie Zheng1
Streptococcal infection is believed to have an intimate relationship with psoriasis, although the pathogenic role
of streptococcal DNA is not fully understood. To gain a clearer understanding of these dynamics, we
investigated the effect of streptococcal DNA on lymphocyte proliferation and activation as well as cytokine
secretion in psoriasis. Peripheral blood mononuclear cells (PBMCs) from psoriatic patients had higher
proliferative responses upon stimulation by streptococcal antigen (SA) when compared with those from healthy
individuals. Strikingly, this enhanced proliferation of PBMCs was attenuated after administration of SA treated
with DNase-I. In addition, CD69 expression levels on T cells, including skin-homing lymphocyte cutaneous
lymphocyte-associated antigen positive T cells, and IFN-a secretion by PBMCs were also attenuated in patients
after stimulation with SA without nucleic acid (non–nucleic acid SA, non-NASA) compared with stimulation with
untreated SA. However, activation marker CD86 expression levels on B cells as well as the secretion of IFN-g and
tumor necrosis factor (TNF)-a following stimulation with SA or non-NASA were not significantly altered.
Interestingly, the attenuated T-cell activation and IFN-a secretion in psoriatic patients could be reconstituted
when stimulated by non-NASA combined with synthetic CpG-A, but not when combined with synthetic CpG-B.
This study demonstrates the integral function of SA, particularly streptococcal DNA, in the pathogenesis of
psoriasis.
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INTRODUCTION
Psoriasis is conventionally considered to be a T-cell-mediated
T helper 1 (Th1)-type inflammatory skin disease characterized
by hyperproliferative keratinocytes and infiltration of promi-
nent T cells, dendritic cells (DCs), and neutrophils (Griffiths
and Barker, 2007). Intralesional T cells expressing the unique
skin-homing determinant cutaneous lymphocyte-associated
antigen (CLA) (Fuhlbrigge et al., 1997), along with other
immune cells such as DCs and neutrophils, induce the
proliferation and abnormal differentiate of keratinocytes
(Prinz, 2003; Bowcock and Krueger, 2005; Gaspari, 2006).
Recent studies have also shown that Th17 cells have an
essential function during psoriatic pathogenesis (Wilson
et al., 2007; Zheng et al., 2007). Th1 and IL-17þ T cells
may collaboratively contribute to psoriasis development
(Kryczek et al., 2008). Although the pathogenesis of psoriasis
is not fully understood, longtime clinical observation
substantiates microbial infection’s intimate relationship with
onset. Group A streptococci (GAS) are a well-recognized
trigger for acute guttate psoriasis and are involved in the
exacerbation of chronic plaque psoriasis (Gudjonsson et al.,
2003). Increased peripheral blood mononuclear cell (PBMC)
responses to the cell walls and membranes of GAS have been
reported in both guttate and chronic plaque psoriasis cases as
compared with control patients (Gross et al., 1977; Baker
et al., 1991). Furthermore, GAS-reactive T cells in skin lesions
of chronic plaque psoriasis can proliferate in response to
streptococcal antigens (SAs), producing IFN-g (Baker et al.,
1999; Brown et al., 2000). Recently, identical TCR rearrange-
ments have also been found in streptococcal angina and skin
lesions of patients with psoriasis vulgaris (Diluvio et al.,
2006). Therefore, infection, especially streptococcal infec-
tion, has been regarded as an initial factor in the activation of
pathogenic T cells in psoriasis.
Thus far, most of the studies concerning the trigger
mechanisms for streptococcal infection-related psoriasis have
focused mainly on its protein antigens. Unfortunately, the
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identities of the SAs recognized by pathogenic T cells have
yet to be determined. In addition to the bacterial proteins, the
role of streptococcal DNA in psoriatic pathogenesis has also
not been fully elucidated.
Bacterial DNA containing unmethylated nucleotides with
the particular sequence motif CG has been recognized as an
immune-stimulatory molecule triggering Th1-type responses
and producing proinflammatory cytokines and chemokines
via innate Toll-like receptor 9 (TLR-9) (Hemmi et al., 2000;
Bauer et al., 2001; Bauer and Wagner, 2002; Krieg, 2002). It
has been reported that streptococcal DNA contains such
stimulatory motifs, thereby inducing a strong immune
reaction (Chatellier and Kotb, 2000; Oshikawa et al., 2006).
Recent studies also suggest that CpG DNA may contribute to
the development and/or progression of some autoimmune
and inflammatory diseases. For example, the anti-DNA
autoantibodies in systemic lupus erythematosus patients
cross-react with bacterial and mammalian DNA (Pisetsky
et al., 1999). Mice immunized with CpG DNA plus a
chlamydia-derived antigen that cross-reacts with a cardiac
antigen develop an autoimmune myocarditis (Bachmaier
et al., 1999). CpG DNA has also been shown to be important
for establishing experimental autoimmune encephalomyeli-
tis, an animal disease model of multiple sclerosis (Ichikawa
et al., 2002; Prinz et al., 2006).
For this study, we hypothesized that streptococcal CpG
DNA may be critical in the pathogenesis of psoriasis. We
examined the effects of streptococcal DNA on the prolifera-
tion, activation, and cytokine secretion of PBMCs in patients
with psoriasis. The levels of PBMCs and T-cell proliferation
and the activation of T cells, including CLAþ T cells, as well
as the production of IFN-a in response to SA stimulation were
found to decrease significantly when bacterial DNA was
devoid of whole SA. However, B-cell activation was not
influenced. These results suggest that streptococcal CpG
DNA may function in the activation of pathogenic T cells,
thus leading to the development of psoriasis. This provides
new insights into the pathogenesis of psoriasis.
RESULTS
Proliferation of PBMCs in psoriatic patients is significantly
higher than in healthy individuals on whole SA stimulation, but
this increased proliferation is attenuated after administration of
whole SA treated with DNase-I
It has been shown that patients with guttate or chronic
plaques show increased PBMC responses to GAS antigens
(Gross et al., 1977; Baker et al., 1991). We therefore
examined the proliferative levels of PBMCs in psoriatic
patients and healthy individuals in response to SA. As shown
in Figure 1a, patient PBMCs indeed showed higher levels of
proliferation in response to SA as compared with those from
healthy individuals, and a significant difference occurred at a
dose of 25 mgml1 (P¼ 0.032, Figure 1a). By contrast, the
proliferative responses to non–nucleic acid streptococcal
antigen (non-NASA) at any dose did not show significant
differences between the patients and the controls (P40.05,
Figure 1b). To examine the net contribution of streptococcal
DNA in PBMC proliferation, the number of counts per minute
(c.p.m.) of PBMCs stimulated with whole SA treated with
DNase-I was subtracted from the c.p.m. of PBMCs stimulated
with whole SA. As indicated in Figure 1c, proliferation of
PBMCs from psoriatic patients was significantly higher than
that of those from healthy individuals at the dose of
25 mgml1 (P¼0.022). These results affirm that streptococcal
infection may be critical in the pathogenesis of psoriasis.
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Figure 1. Peripheral blood mononuclear cells (PBMCs) from psoriatic
patients have a higher proliferative response to streptococcal antigen (SA)
than cells from healthy individuals. PBMCs from psoriatic patients (n¼15)
and healthy individuals (n¼ 10) were stimulated with SA (a) or non–nucleic
acid SA (non-NASA) (b). After 72 hours of culture, cellular proliferation was
determined by thymidine incorporation. Panel c shows the net contribution of
streptococcal DNA stimulation (Dc.p.m.). The c.p.m. value from non-NASA-
stimulated PBMCs was subtracted from the c.p.m. value from whole SA-
stimulated PBMCs. Data represent mean±SD of tested individuals. *Po0.05
compared with healthy individuals. c.p.m., counts per minutes;
NS, no significance.
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To further assess the role of streptococcal DNA in the
pathogenesis of psoriasis, we assessed PBMC proliferation
when stimulated with whole SA or non-NASA. We found that
the proliferation of PBMCs from psoriatic patients upon
stimulation with any dose of non-NASA was significantly
attenuated as compared with that stimulated by SA
(Po0.001, Figure 2a), whereas in PBMCs from healthy
individuals, only lower doses of non-NASA induced sig-
nificantly lower responses as compared with whole SA
(P¼0.002 and 0.016, respectively, Figure 2b). Similar levels
of proliferation were observed between the responses to
non-NASA and SA at the dose of 25 mgml1 (P¼0.510,
Figure 2b). The decreased proliferation is not due to
DNase-I treatment as the addition of DNase-I-treated or
untreated phytohemagglutinin induced similar levels of
PBMC proliferation in cells from both patients and healthy
individuals (P¼0.165 and 0.099, respectively). These results
suggest that streptococcal DNA may indeed participate in the
process of immune response triggered by streptococcus
in psoriasis.
Decreased T-cell proliferation, expression of CD69 on both
whole T cells and CLAþ T cells, and IFN-a production upon
stimulation with SA devoid of bacterial DNA in psoriatic
patients’ PBMCs
Next, we examined the effect of streptococcal DNA on T-cell
proliferation and activation, including the skin-homing CLAþ
T-cell activation in psoriatic patients. We found that the
proliferation of T cells from patients upon stimulation with
non-NASA was significantly reduced as compared with that
stimulated by SA (P¼0.041, Figure 3a). Furthermore, both SA
and non-NASA induced the activation of whole T cells and
CLAþ T cells as measured by CD69 expression (Figure 3b
and c). However, stimulation of PBMCs from patients with SA
resulted in upregulation of CD69 at 10.44% of whole T cells
and 0.5% of CLAþ T cells compared with 9.24% of whole
T cells and 0.35% of CLAþ T cells activated by SA devoid of
bacterial DNA (P¼0.012 and 0.042, respectively, Figure 3b
and c). By contrast, there was no significant difference in
CD69 expression on whole T cells from healthy individuals
when stimulated with SA or non-NASA (7.08 vs 6.28%,
P¼0.181, Figure 3b). Consistent with the result for whole
T cells, similar levels of CD69 expression on CLAþ T cells
were observed on stimulation with SA or non-NASA in
healthy PBMCs (0.35 vs 0.32%, P¼0.670, Figure 3c).
It has been shown that bacterial DNA can activate B cells
to proliferate, secrete IgM and cytokine IL-10, and upregulate
surface molecule expression such as with HLA-DR and co-
stimulatory molecules (Decker et al., 2000). We examined
the effects of streptococcal DNA on B cells regarding the
expression of the co-stimulatory molecule CD86 in patient
cells. No significant difference was found in the expression of
CD86 on B cells induced by SA and by non-NASA (39.42 vs
40.27%, P¼ 0.668, Figure 4a) at 2 mgml1 SA stimulation.
The cytokines IFN-a, IFN-g, and TNF-a have been shown
to be important in psoriasis. Therefore, we examined the
cytokine secretion produced by PBMCs from patients. Both
SA and non-NASA induced significant levels of IFN-a, IFN-g,
and TNF-a (Figure 4b). The stimulation of PBMCs with SA
resulted in a significant amount of IFN-a production as
compared with stimulation with non-NASA (P¼0.003,
Figure 4b). However, the levels of IFN-g and TNF-a were
similar when PBMCs were stimulated with SA or non-NASA
(P40.05, Figure 4b). Furthermore, we found that IFN-g was
secreted mainly by T cells, and not plasmacytoid DCs (pDCs),
in response to SA and non-NASA (Supplementary Figure S1a).
However, there was no significant difference between SA and
non-NASA (2.07 vs. 1.71%, P¼ 0.263, Supplementary Figure
S1b). This is not very surprising given that pDCs are
predominately type I IFN producers. Taken together, these
results indicate that streptococcal DNA may aid in the
activation of pathogenic T cells through IFN-a secretion,
leading to the development of psoriasis.
Combining non-NASA with CpG-A, but not with CpG-B,
induces enhanced T-cell activation in psoriatic patients
CpG-A and CpG-B are synthetic oligodeoxynucleotides
(ODNs) containing CpG motifs. CpG-B preferentially
activates B cells, whereas CpG-A predominately activates
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Figure 2. DNase-I treatment significantly attenuates the enhanced
peripheral blood mononuclear cell (PBMC) proliferation mediated by
streptococcal antigen (SA). PBMCs from psoriatic patients (n¼ 15, panel a)
and healthy individuals (n¼10, panel b) were stimulated with DNase-I-
treated or untreated SA. Phytohemagglutinin was used as positive control to
stimulate T-cell proliferation. After 72 hours of culture, cellular proliferation
was determined by thymidine incorporation. Data represent mean±SD of
tested individuals. *Po0.05, **Po0.01.
NS, no significance.
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pDCs. To determine which type of CpG could be integrated
with streptococcal protein antigens to induce T-cell activa-
tion, CpG-A or CpG-B was mixed with non-NASA in PBMC
culture. As shown in Figure 5a and b, a combination of
non-NASA with CpG-A resulted in significantly enhanced
T-cell activation in psoriatic patients’ cells. In addition, CLAþ
T cells were also upregulated after stimulation with CpG-A
plus non-NASA. By contrast, CD69 expression on whole
T cells or CLAþ T cells was not significantly changed upon
stimulation with the combination of non-NASA and CpG-B.
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Figure 3. Streptococcal antigen (SA) induces higher levels of T-cell proliferation and CD69 expression in peripheral blood mononuclear cells (PBMCs) from
psoriatic patients. (a) Peripheral T cells from psoriatic patients (n¼ 5) were sorted and stimulated with SA (2 mgml1), non–nucleic acid SA (non-NASA)
(2 mgml1), or medium as a control in the presence of mitomycin-treated antigen-presenting cells. After 72 hours of culture, cellular proliferation was determined
by thymidine incorporation. Data represent mean±SD of tested individuals. *Po0.05. (b and c) PBMCs from psoriatic patients (n¼ 20) and healthy volunteers
(n¼12) were stimulated with SA (2 mgml1), non-NASA (2 mgml1) ,or medium as a control. After 24 hours of culture, cells were harvested, stained with
appropriate antibodies, and analyzed for the expression of CD69 on CD3þ T cells (b) or CLAþ CD3þ T cells (c). One representative dot plot from a patient or
healthy individual is shown in each panel. Data represent mean±SD of tested individuals and are presented as a percentage of CD3þ T cells and CLAþ CD3þ
T cells expressing CD69. *Po0.05. NS, no significance.
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Neither CpG-A nor CpG-B alone appeared to activate whole
T cells or CLAþ T cells as compared with the medium. In
addition, non-NASA combined with CpG-A, but not with
CpG-B, induced significantly higher levels of IFN-a produc-
tion than did non-NASA stimulation alone (P¼0.014, Figure
5c). Because CpG-A mainly activates pDCs, we assume that
streptococcal DNA may enhance the activation of patho-
genic T cells through pDC activation and IFN-a production.
To further investigate this hypothesis, we compared T-cell
proliferation levels with SA in the presence or absence of
pDCs in the patient cells. The proliferative responses to SA by
T cells in the absence of pDCs were lower than those with the
whole antigen-presenting cells. However, T cells still
proliferated in the absence of pDCs (data not shown). In
addition, it has been reported that pDCs in the peripheral
blood of psoriatic patients significantly decreased compared
with those in the blood of healthy individuals (Nestle et al.,
2005). In our study, we also observed a significantly lower
frequency of pDCs in the peripheral blood from patients (0.58
vs 0.23%, P¼0.014, Supplementary Figure S2a). However,
the levels of IFN-a secreted by PBMCs upon stimulation with
SA were similar between cells from patients and cells from
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Figure 4. Streptococcal antigen (SA) induces higher levels of IFN-a
production in psoriatic patients but has no effect on B-cell activation and
IFN-c and TNF-a production. (a) Peripheral blood mononuclear cells from 20
psoriatic patients were stimulated with SA (2mgml1), non–nucleic acid SA
(non-NASA) (2 mgml1), or medium as a control. After 24 hours of culture,
cells were harvested, stained with appropriate antibodies, and analyzed for
the expression of CD86 on CD19þ B cells. Data represent mean±SD of
tested individuals and are presented as a percentage of CD19þ B cells
expressing CD86. NS, no significance. (b) Cytokine levels were measured
with cell-free supernatants by ELISA. Data represent mean±SD of tested
individuals. **Po0.01. NS, no significance.
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Figure 5. Combined stimulation with non–nucleic acid SA (non-NASA) and
CpG-A induces enhanced activation of T cells and IFN-a production in
peripheral blood mononuclear cells (PBMCs) from 12 psoriatic patients.
PBMCs from 12 psoriatic patients were stimulated with non-NASA
(2 mgml1), non-NASA (2 mgml1) plus CpG-A or plus CpG-B (5 mgml1), or
CpG-A or CpG-B (5 mgml1) alone, or medium as a control. After 24 hours
of culture, cells were harvested, stained with appropriate antibodies, and
analyzed for the expression of CD69 on CD3þ T cells (a) and CLAþ CD3þ
T cells (b). Data represent mean±SD of tested individuals and are presented
as a percentage of CD3þ T cells or CLAþ CD3þ T cells expressing CD69,
respectively. Also, IFN-a level was measured with cell-free supernatants by
ELISA (c). Data represent mean±SD of tested individuals. *Po0.05.
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healthy individuals (P40.05, Supplementary Figure S2b).
These results suggest that pDCs from psoriatic patients may
have been activated, thus secreting large amounts of IFN-a.
DISCUSSION
In this study, we showed that PBMCs from psoriatic patients
had significantly higher proliferation and T-cell activation
upon SA stimulation. However, the enhanced proliferation
and T-cell activation as well as IFN-a secretion were
attenuated after stimulation with SA devoid of bacterial
DNA. Strikingly, the decreased T-cell activation and IFN-a
secretion could be reconstituted by stimulation with non-
NASA combined with CpG-A but not when combined with
CpG-B. These data suggest that streptococcal DNA indeed
participates in the progress of pathogenic immune reaction
triggered by streptococcus in psoriasis.
We found that blood from psoriatic patients had sig-
nificantly higher PBMC proliferation in response to SA
stimulation than did that from healthy volunteers. In addition,
psoriatic patients’ cells showed pronounced response to
streptococcal DNA stimulation, which may be related to
increased expression of TLR-9 in patients (unpublished
observation). This may also explain why we did not see any
significant difference when PBMCs from either patients or
healthy individuals were stimulated with non-NASA. Further-
more, we examined the effect of streptococcal DNA on T-cell
proliferation and activation, including the skin-homing CLAþ
T-cell activation. In patients, T-cell proliferation upon
stimulation with non-NASA was significantly attenuated as
compared with that stimulated by SA. Also, SA stimulation of
PBMCs from patients resulted in significant upregulation of
CD69 on whole T cells and CLAþ T cells compared with
non-NASA stimulation. This is consistent with a previous
report showing persistent CD69 expression on the local
infiltrating T cells in psoriatic patients (Torres-Alvarez et al.,
2007). However, among healthy controls there was no
significant difference in expression of CD69 on whole T
cells and CLAþ T cells induced by SA and non-NASA. In
addition, in contrast to psoriatic patients, neither SA nor non-
NASA could activate CLAþ T cells in the blood from healthy
volunteers. These results suggest that T cells from patients
have a higher sensitivity to stimulation by streptococcal
DNA. The increased T-cell proliferation and activation may
correspond with disease development, as implicated by a
previous report describing psoriatic patients as having a
higher frequency of circulation CLAþ T cells, and they
closely correlate with the severity of their disease (Sigmunds-
dottir et al., 2001). Taken together, our findings show that
streptococcal CpG DNA may participate in the development
of psoriasis by increasing the activation of pathogenic T cells.
Interestingly, we found that the decreased activation of
T cells stimulated by non-NASA alone could be reconstituted
by the combined stimulation of non-NASA plus CpG-A, but
not by combination with CpG-B. This result is not associated
with the direct contribution of CpG-A because neither of
them is able to trigger the activation of T cells directly. It has
been shown that CpG-A predominantly activates pDCs and
induces high levels of IFN-a production, whereas CpG-B is
superior in activating B cells (Krieg, 2002; Vollmer et al.,
2004). Therefore, we speculate that streptococcal DNA may
increase the activation of pathogenic T cells through the
activation of pDCs and production of IFN-a. This notion is
supported by a recent finding that IFN-a derived from pDCs
activates and expands pathogenic T cells, causing the
development of skin lesions such as psoriasis (Nestle et al.,
2005). In addition, IFN-a therapy has been reported to
exacerbate psoriasis in a patient with chronic hepatitis C
infection (Yurci et al., 2007). Our data also showed that
PBMCs stimulated with SA, but not non-NASA, produced a
significant amount of IFN-a. Furthermore, the decreased
IFN-a secretion could be reconstituted by the combined
stimulation of non-NASA with CpG-A. In addition, consistent
with the previous report (Nestle et al., 2005), we observed a
decreased pDC frequency in the peripheral blood from
psoriatic patients. However, there was no significant differ-
ence in IFN-a production by PBMCs stimulated with SA
between patients and healthy controls. Our data suggest that
pDCs from psoriatic patients may have been activated, thus
secreting large amounts of IFN-a. Indeed, it has been shown
that the aberrant activation of pDCs triggers IFN-associated
autoimmunity in psoriasis (Lande et al., 2007; Gilliet and
Lande, 2008).
We also noticed a lower T-cell proliferative response in
the absence of pDCs compared with the whole antigen-
presenting cells. However, T cells still proliferate in the
absence of pDCs. Escherichia coli DNA has been shown to
upregulate CD40 expression on human myeloid DCs, pDCs,
and monocytes (Pichyangkul et al., 2001). Therefore, it is
possible that when PBMCs are stimulated with SA, myeloid
DCs or monocytes may inducibly express TLR-9 and co-
stimulatory molecules to complement pDCs for T-cell
proliferation. Further investigation is under way to confirm
this result by enlarging sample sizes.
In addition, we did not observe any significant differences
in IFN-g and TNF-a production by PBMCs from patients
stimulated with SA and non-NASA. This may be attributable
to other immunostimulatory components of streptococcus,
such as peptidoglycan, which alternatively induce secretion
of these cytokines (Takeda et al., 2003).
We also found effects of streptococcal DNA on B-cell
activation in cells from patients. However, no significant
difference was found for the expression of CD86 on B cells
stimulated with SA or non-NASA. In contrast to the enhanced
T-cell activation mediated by non-NASA and CpG-A, the
combined stimulation of non-NASA with CpG-B resulted in a
significant upregulation of CD86 on B cells as compared with
the non-NASA stimulation alone (data not shown). This result
is perhaps due to the direct activation induced by CpG-B
when B cells are stimulated with CpG-A or CpG-B,
respectively. On the basis of the current findings, we
conclude that streptococcal DNA has a similar effect on
activating T cells as CpG-A, which may explain the role of
streptococcal DNA in the development of psoriasis.
In conclusion, our study shows that SA without nucleic
acid decreases the proliferation of PBMCs and activation of
T cells, suggesting that streptococcal DNA may be complicit
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in the activation of pathogenic T cells, thus leading to the
development of psoriasis.
MATERIALS AND METHODS
Patients
Patients with psoriasis vulgaris were diagnosed on the basis of
clinical and histopathologic criteria (Schon and Boehncke, 2005).
PBMCs from 15 patients aged 10–70 years (mean 38±21) were used
to assess the proliferation induced by various stimuli. In addition,
PBMCs from a second set of 20 patients with similar characteristics
(ages ranging from 10 to 77 years, mean 45±19) were used for flow
cytometry analysis and ELISA. The patients had not been treated with
systemic therapy for at least 4 weeks before study entry and were
using only topical emollients. As controls, blood samples from 10 or
12 age-matched healthy volunteers were used. The study was
approved by the Shanghai Jiao Tong University School of Medicine
Research Ethics Committee and conducted according to the
Declaration of Helsinki Principles. All the participants in this study
gave their written informed consent.
Preparation of SA
SA was prepared from group A b-hemolytic streptococcus serotype
M6 (catalog no. CMCC (B) 32175, China Centre for Type Culture
Collection, Wuhan, Hubei, China). The bacteria were cultured on
blood agar and incubated in Todd-Hewitt broth (Oxoid, Hampshire,
UK) at 371C for 14–16 hours. After centrifugation, the pellets were
washed twice in phosphate-buffered saline and then resuspended
and sonicated. To prepare DNA-free SA (non-NASA), the SA was
mixed with DNase-I (Roche Applied Science, Mannheim, Germany)
to a final concentration of 1mgml1 and incubated at 371C for
30minutes. Complete digestion of bacterial DNA was confirmed by
agarose gel electrophoresis. In some experiments, DNA-free SA was
prepared by anion exchange chromatography (Q Sepharose XL; GE
Healthcare, formerly Amersham Biosciences, Piscataway, NJ).
CpG ODNs
CpG ODNs were synthesized by Sigma-Genosys (St Louis, MO). All
of the following sequences are 50–30; lowercase letters are 50 of
phosphothiorate linkages and uppercase letters are 50 of phospho-
diester linkages. The sequences of the ODNs were CpG-A,
ggTGCATCGATGCAGggggg, and CpG-B, tcgtcgttttgtcgttttgtcgtt.
Isolation of PBMCs
Human PBMCs were isolated from heparinized blood by density
gradient centrifugation over Ficoll-Hypaque and resuspended in RPMI
1640 medium (GIBCO/Invitrogen, Life Technologies, Carlsbad, CA),
supplemented with 10% fetal bovine serum, penicillin/streptomycin,
2mM glutamine, and 25mM HEPES (GIBCO/Invitrogen).
Isolation of peripheral T cells
PBMCs isolated from heparinized blood were suspended in sterile cell
sorting medium containing 1 Hanks’ balanced salt solution (GIBCO/
Invitrogen), 2% heat-inactivated fetal bovine serum (GIBCO/Invitro-
gen), 10mM HEPES buffer (GIBCO/Invitrogen), and 30mgml1 of
gentamicin (GIBCO/Invitrogen). Cells were incubated with saturating
concentrations of directly labeled anti-human CD3-PE-Cy5.5 (clone
S4.1, Caltag/Invitrogen, Carlsbad, CA) mAb for 30minutes on ice,
washed twice in cell sorting medium, and resuspended in cell sorting
medium. CD3þ T cells were isolated from PBMCs by live sterile cell
sorting (FACSVantage SE, Becton Dickinson, Mountain View, CA).
CD3 cells were treated with mitomycin (Alexis Biochemicals, San
Diego, CA) as antigen-presenting cells for T-cell proliferation assay. In
some experiments, cells were incubated with anti-human CD3
PE-Cy5.5 and anti-human BDCA-2-FITC (clone AC144, Miltenyi
Biotec, Bergisch Gladbach, Germany) mAbs. CD3 BDCA-2þ cells
and CD3 BDCA-2 cells were sorted for study.
Proliferation assay
Fresh PBMCs, or peripheral T cells in the presence of mitomycin-
treated antigen-presenting cells, were cultured in 96-well plates for 3
days with SA or non-NASA in a total volume of 200 ml. As a control,
the maximal amount of DNase-I used in non-NASA was added to
cultures of PBMCs with phytohemagglutinin (1 mgml1). Cultured
cells were pulsed with 3H-thymidine (1mCi per well, Shanghai
Institute of Applied Physics, Chinese Academy of Science, Shanghai,
China) 16 hours before cell harvest. Proliferation was determined by
thymidine incorporation measured in a b-scintillation counter and
expressed as the mean c.p.m. of three replicates.
Flow cytometry analysis
Fresh PBMCs from patients and healthy volunteers were cultured in
24-well plates for 24 hours with optimal concentrations of SA or
non-NASA. PBMCs from patients were further stimulated with non-
NASA plus CpG ODNs (5mgml1) or CpG ODNs alone (5 mgml1).
To analyze CD69 expression on whole T cells or CLAþ T cells
and CD86 on B cells from patients, PBMCs were stained with anti-
human CD3-PE-Cy5 (clone UCHT1), anti-human CLA-FITC (clone
HECA-452), and anti-human CD69-PE (clone FN50) or anti-
human CD19-FITC (clone HIB19) and anti-human CD86-PE (clone
2331(FUN-1)) (all antibodies from BD Pharmingen, San Diego, CA)
for 30minutes on ice. Cells were washed twice with phosphate-
buffered saline containing 3% fetal bovine serum, resuspended in
1% paraformaldehyde, and analyzed. A total of 20,000 events were
analyzed per sample with the FACS Calibur (Becton Dickinson, San
Jose, CA).
Detection of cytokines
Fresh PBMCs from patients were cultured in 24-well plates for
24 hours with optimal concentrations of SA and non-NASA. The
culture supernatants were harvested and tested for the presence of
cytokines IFN-a (Adlitteram Diagnostic Laboratories, San Diego,
CA), IFN-g, and TNF-a (Diaclone, Stamford, CT) by ELISA.
Statistical analysis
Data were expressed as mean±SD of tested individuals. Statistical
significance was determined using a paired t-test among patients or
healthy individuals and the Student’s t-test or non-parametric two-
tailed tests between patients and healthy individuals. Po0.05 was
considered significant.
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